Functionalization
Extracellular vesicles (EVs) possess remarkable qualities, including high cellular uptake, low immunogenicity, excellent biocompatibility, and the ability to easily cross the blood-brain barrier, making them a promising generation of drug delivery platforms.
Nevertheless, the inherent lack of specificity in EVs presents a notable challenge. While EVs are acclaimed for their ability to transport biological cargo to target cells, our specialization lies in customizing EVs to enhance their therapeutic impact.
| Functionalization | Payload | Methods |
|---|---|---|
| Loading |
|
|
| Surface modification |
|
|
Case Study EV-nanobody: specific uptake into target cells
experiments with mouse 4T1 cells that co-express tdTomato and human EGFR, and parental 4T1 cells. RBCEVs,
labeled with CFSE (green), show enhanced intracellular accumulation in tdTomato-hEGFR double-positive 4T1
cells (red), while no accumulation is observed in tdTomato-hEGFR double-negative parental 4T1 cells (blue).
Case Study EV-nanobody-nucleic acid: in vitro therapeutic effect
GFP in CA1a-dGFP cells (top image). RBCEVs loaded with antisense oligonucleotides (ASOs) against miR-125b,
a tumorigenic microRNA, demonstrated a ~10-fold greater reduction with EGFR-targeted RBCEVs compared to
non-targeted ones (bottom left image). Furthermore, EGFR-targeted RBCEVs loaded with miR-125b ASOs
significantly reduced 4T1 cell viability to ~20% compared to the untreated control (bottom right image).
Case Study EV-nanobody-nucleic acid: in vivo therapeutic effect
